NCT03202667View on ClinicalTrials.gov

Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

August 26, 2021

Study Completion Date

December 6, 2021

Conditions
SIAD - Syndrome of Inappropriate AntidiuresisHyponatremia
Interventions
DRUG

Empagliflozin 25mg

Treatment with empagliflozin 25mg once daily for 28 days

DRUG

Placebo

Treatment with Placebo oral tablet once daily for 28 days

Trial Locations (1)

4031

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT03202667 - Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study | Biotech Hunter | Biotech Hunter